RU2007140733A - Диариламинсодержащие соединения и композиции, и их применение в качестве модуляторов ядерных рецепторов стероидного гормона - Google Patents
Диариламинсодержащие соединения и композиции, и их применение в качестве модуляторов ядерных рецепторов стероидного гормона Download PDFInfo
- Publication number
- RU2007140733A RU2007140733A RU2007140733/04A RU2007140733A RU2007140733A RU 2007140733 A RU2007140733 A RU 2007140733A RU 2007140733/04 A RU2007140733/04 A RU 2007140733/04A RU 2007140733 A RU2007140733 A RU 2007140733A RU 2007140733 A RU2007140733 A RU 2007140733A
- Authority
- RU
- Russia
- Prior art keywords
- halogen
- alkyl
- compound
- alkoxy
- aryl
- Prior art date
Links
- 0 CC1(C#N)SC(N(*)C2=I*=C(*)C3=C2**3)=N*(*)C=C1 Chemical compound CC1(C#N)SC(N(*)C2=I*=C(*)C3=C2**3)=N*(*)C=C1 0.000 description 7
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/46—Oxygen atoms
- C07D213/50—Ketonic radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66903005P | 2005-04-06 | 2005-04-06 | |
| US60/669,030 | 2005-04-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2007140733A true RU2007140733A (ru) | 2009-05-20 |
Family
ID=37073811
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007140733/04A RU2007140733A (ru) | 2005-04-06 | 2006-04-06 | Диариламинсодержащие соединения и композиции, и их применение в качестве модуляторов ядерных рецепторов стероидного гормона |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1865775A1 (fr) |
| JP (1) | JP2008536835A (fr) |
| KR (1) | KR100926399B1 (fr) |
| CN (1) | CN101184395A (fr) |
| AU (1) | AU2006232109A1 (fr) |
| BR (1) | BRPI0608934A2 (fr) |
| CA (1) | CA2603250A1 (fr) |
| MX (1) | MX2007012449A (fr) |
| RU (1) | RU2007140733A (fr) |
| WO (1) | WO2006108107A1 (fr) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9512125B2 (en) | 2004-11-19 | 2016-12-06 | The Regents Of The University Of California | Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents |
| KR20120051760A (ko) | 2006-04-04 | 2012-05-22 | 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 | 키나제 길항물질 |
| US9604931B2 (en) | 2007-01-22 | 2017-03-28 | Gtx, Inc. | Nuclear receptor binding agents |
| CN101641013B (zh) * | 2007-01-22 | 2014-07-30 | Gtx公司 | 核受体结合剂 |
| US9623021B2 (en) | 2007-01-22 | 2017-04-18 | Gtx, Inc. | Nuclear receptor binding agents |
| US20110160232A1 (en) | 2007-10-04 | 2011-06-30 | Pingda Ren | Certain chemical entities and therapeutic uses thereof |
| MX2010007418A (es) | 2008-01-04 | 2010-11-12 | Intellikine Inc | Ciertas entidades quimicas, composiciones y metodos. |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| SG187502A1 (en) | 2008-02-01 | 2013-02-28 | Takeda Pharmaceutical | Oxim derivatives as hsp90 inhibitors |
| JP5547099B2 (ja) | 2008-03-14 | 2014-07-09 | インテリカイン， エルエルシー | キナーゼ阻害剤および使用方法 |
| WO2009114874A2 (fr) | 2008-03-14 | 2009-09-17 | Intellikine, Inc. | Inhibiteurs de kinases (benzothiazole) et procédés d’utilisation associés |
| JP5788316B2 (ja) | 2008-07-08 | 2015-09-30 | インテリカイン， エルエルシー | キナーゼインヒビターおよび使用方法 |
| US20110224223A1 (en) | 2008-07-08 | 2011-09-15 | The Regents Of The University Of California, A California Corporation | MTOR Modulators and Uses Thereof |
| JP5731978B2 (ja) | 2008-09-26 | 2015-06-10 | インテリカイン， エルエルシー | 複素環キナーゼ阻害剤 |
| CA2740885C (fr) | 2008-10-16 | 2018-04-03 | The Regents Of The University Of California | Inhibiteurs d'heteroarylkinase a noyau fusionne |
| US8476282B2 (en) | 2008-11-03 | 2013-07-02 | Intellikine Llc | Benzoxazole kinase inhibitors and methods of use |
| ES2547124T3 (es) | 2009-04-02 | 2015-10-01 | Merck Patent Gmbh | Inhibidores de autotaxina |
| JP5789252B2 (ja) | 2009-05-07 | 2015-10-07 | インテリカイン， エルエルシー | 複素環式化合物およびその使用 |
| WO2011047384A2 (fr) | 2009-10-16 | 2011-04-21 | The Regents Of The University Of California | Procédés d'inhibition de l'activité ire1 |
| ME02186B (me) | 2009-12-23 | 2016-02-20 | Takeda Pharmaceuticals Co | Fuzionisani heteroaromatski pirolidinoni kao syk inhibitori |
| US8604032B2 (en) | 2010-05-21 | 2013-12-10 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
| CN103298474B (zh) | 2010-11-10 | 2016-06-29 | 无限药品股份有限公司 | 杂环化合物及其用途 |
| WO2012097000A1 (fr) | 2011-01-10 | 2012-07-19 | Pingda Ren | Procédés de préparation d'isoquinolinones et de formes solides d'isoquinolinones |
| AR085397A1 (es) | 2011-02-23 | 2013-09-25 | Intellikine Inc | Combinacion de inhibidores de quinasa y sus usos |
| JP6026525B2 (ja) | 2011-06-22 | 2016-11-16 | 武田薬品工業株式会社 | 置換６−アザ−イソインドリン−１−オン誘導体 |
| EP2734530A1 (fr) | 2011-07-19 | 2014-05-28 | Infinity Pharmaceuticals, Inc. | Composés hétérocycliques et leurs utilisations |
| EP2734520B1 (fr) | 2011-07-19 | 2016-09-14 | Infinity Pharmaceuticals, Inc. | Composés hétérocycliques et leurs utilisations |
| CA2846431A1 (fr) | 2011-08-29 | 2013-03-07 | Infinity Pharmaceuticals Inc. | Composes heterocycliques et leurs utilisations |
| AU2012341028C1 (en) | 2011-09-02 | 2017-10-19 | Mount Sinai School Of Medicine | Substituted pyrazolo[3,4-D]pyrimidines and uses thereof |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| IN2014KN02601A (fr) | 2012-04-24 | 2015-05-08 | Vertex Pharma | |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| CA2886240A1 (fr) | 2012-09-26 | 2014-04-03 | The Regents Of The University Of California | Modulation de ire1 |
| PT3527563T (pt) | 2013-03-12 | 2021-12-09 | Vertex Pharma | Inibidores de adn-pk |
| US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
| DK3052485T3 (da) | 2013-10-04 | 2021-10-11 | Infinity Pharmaceuticals Inc | Heterocykliske forbindelser og anvendelser deraf |
| WO2015051241A1 (fr) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Composés hétérocycliques et leurs utilisations |
| DK3057953T3 (en) | 2013-10-17 | 2018-11-19 | Vertex Pharma | CO CRYSTALS OF (S) -N-METHYL-8- (1 - ((2'-METHYL- [4,5'-BIPYRIMIDIN] -6-YL) AMINO) PROPAN-2-YL) QUINOLIN-4-CARBOXAMIDE AND DEUTERATED DERIVATIVES THEREOF AS DNA-PK INHIBITORS |
| SG11201607705XA (en) | 2014-03-19 | 2016-10-28 | Infinity Pharmaceuticals Inc | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
| WO2015160975A2 (fr) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Polythérapies |
| US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
| WO2017048702A1 (fr) | 2015-09-14 | 2017-03-23 | Infinity Pharmaceuticals, Inc. | Formes solides de dérivés d'isoquinolinone, leur procédé de fabrication, compositions les comprenant et méthodes d'utilisation de celles-ci |
| WO2017161116A1 (fr) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues de composés isoquinolinone et quinazolinone et leurs utilisations comme inhibiteurs de la kinase pi3k |
| US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US11147818B2 (en) | 2016-06-24 | 2021-10-19 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| CA3038657A1 (fr) | 2016-09-27 | 2018-04-05 | Vertex Pharmaceuticals Incorporated | Methode de traitement du cancer utilisant une combinaison d'agents endommageant l'adn et d'inhibiteurs de la dna-pk |
| WO2021257863A1 (fr) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Composés de pyrrolotriazine utilisés en tant qu'inhibiteurs de v617f de jak2 |
| WO2021257857A1 (fr) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Composés naphtyridinone en tant qu'inhibiteurs de jak2 v617f |
| US11767323B2 (en) | 2020-07-02 | 2023-09-26 | Incyte Corporation | Tricyclic pyridone compounds as JAK2 V617F inhibitors |
| AU2021300429A1 (en) | 2020-07-02 | 2023-02-16 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
| US11661422B2 (en) | 2020-08-27 | 2023-05-30 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
| US11919908B2 (en) | 2020-12-21 | 2024-03-05 | Incyte Corporation | Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors |
| JP2024507935A (ja) | 2021-02-25 | 2024-02-21 | インサイト・コーポレイション | Ｊａｋ２ ｖ６１７ｆ阻害剤としてのスピロ環式ラクタム |
| CA3237199A1 (fr) | 2021-11-02 | 2023-05-11 | Flare Therapeutics Inc. | Agonistes inverses de pparg et leurs utilisations |
-
2006
- 2006-04-06 MX MX2007012449A patent/MX2007012449A/es unknown
- 2006-04-06 WO PCT/US2006/012915 patent/WO2006108107A1/fr active Application Filing
- 2006-04-06 BR BRPI0608934-8A patent/BRPI0608934A2/pt not_active IP Right Cessation
- 2006-04-06 EP EP06749458A patent/EP1865775A1/fr not_active Withdrawn
- 2006-04-06 JP JP2008505543A patent/JP2008536835A/ja active Pending
- 2006-04-06 KR KR1020077025658A patent/KR100926399B1/ko not_active IP Right Cessation
- 2006-04-06 CA CA002603250A patent/CA2603250A1/fr not_active Abandoned
- 2006-04-06 AU AU2006232109A patent/AU2006232109A1/en not_active Abandoned
- 2006-04-06 RU RU2007140733/04A patent/RU2007140733A/ru not_active Application Discontinuation
- 2006-04-06 CN CNA2006800187238A patent/CN101184395A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN101184395A (zh) | 2008-05-21 |
| KR100926399B1 (ko) | 2009-11-12 |
| EP1865775A1 (fr) | 2007-12-19 |
| MX2007012449A (es) | 2007-12-05 |
| CA2603250A1 (fr) | 2006-10-12 |
| JP2008536835A (ja) | 2008-09-11 |
| AU2006232109A1 (en) | 2006-10-12 |
| BRPI0608934A2 (pt) | 2010-02-17 |
| WO2006108107A1 (fr) | 2006-10-12 |
| KR20080003403A (ko) | 2008-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2007140733A (ru) | Диариламинсодержащие соединения и композиции, и их применение в качестве модуляторов ядерных рецепторов стероидного гормона | |
| RU2009127642A (ru) | 1-замещенные производные имидазола и их применение в качестве ингибиторов альдостеронсинтазы | |
| DK3100727T3 (en) | Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases | |
| CA2536136A1 (fr) | Imidazoquinolines substituees par aryloxy et arylalkyleneoxy | |
| JP5331691B2 (ja) | Ｂｃｌタンパク質と結合パートナーとの相互作用を阻害する化合物および方法 | |
| RU2009110442A (ru) | Конденсированные производные имидазола для лечения нарушений, опосредованных альдостеронсинтазой, и/или 11-бета-гидроксилазой, и/или ароматазой | |
| US20070099938A1 (en) | Antistress drug and medical use thereof | |
| CN101616587A (zh) | 吲唑化合物 | |
| RU2008142600A (ru) | Органическое соединение | |
| EA202090658A1 (ru) | Ингибиторы кэп-зависимой эндонуклеазы | |
| AU2015306662A1 (en) | Compounds and methods for inhibiting histone demethylases | |
| IL177291A0 (en) | Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | |
| WO2020160295A1 (fr) | Composés bi-fonctionnels et procédés d'ubiquitination ciblée du récepteur des androgènes | |
| BRPI0611828A2 (pt) | antiandrógenos não-esterioidais direcionados a hélice 12 | |
| DK1856045T3 (da) | 1-eddikesyreindolderviater med PGD2-antagonisteffekt | |
| KR20070045272A (ko) | 2-페닐피리딘 유도체 | |
| JP2006508970A5 (fr) | ||
| ES2771748T3 (es) | Antiandrógenos y moduladores selectivos de los receptores de andrógenos no esteroidales con un resto de piridilo | |
| WO2004002530A1 (fr) | Remede pour maladie chronique | |
| RU2009118254A (ru) | Фенилацетамиды в качестве ингибиторов протеинкиназ | |
| DK2546231T3 (en) | alkylamine | |
| FR2943669A1 (fr) | Derives de nicotinamide,leur preparation et leur application en therapeutique | |
| RU2011125917A (ru) | Производные фенилпиримидона, фармацевтические композиции, способы их получения и применения | |
| AU2018274652A1 (en) | Dual modulators of farnesoid X receptor and soluble epoxide hydrolase | |
| BG106924A (bg) | Заместени производни на n-бензил-индол-3-ил-глиоксиловаta киселина с противотуморно действие |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20101123 |